Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
Givosiran Meets Primary and Majority of Secondary Endpoints, with Significant Reduction in Annualized Rate of Composite Porphyria Attacks Relative to Placebo ?
- Alnylam Intends to Complete Filing of New Drug Application (NDA) and Marketing Authorisation Application (MAA) in mid-2019 ?
- Full Results to be Presented at the?European Association for the Study?of the Liver?(EASL) International Liver Congress? in April ?
- Alnylam to Host Conference Call Today at?8:00 a.m. EST??
CAMBRIDGE, Mass.---?Alnylam Pharmaceuticals, Inc.?(Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP), met its primary efficacy endpoint and the majority of secondary endpoints. Specifically, givosiran met the primary endpoint of reduction in the annualized rate of composite porphyria attacks relative to placebo (p less than 0.00000001) and achieved statistically significant results for five of nine secondary endpoints (p less than 0.0001), with a safety and tolerability profile that the Company believes is encouraging, especially in this high unmet disease. Based on these results, the Company plans to complete its rolling submission of a New Drug Application (NDA) and file a Marketing Authorisation Application (MAA) in mid-2019. ?Patients living with AHP experience debilitating and sometimes life-threatening neurovisceral attacks as well as chronic disease manifestations which negatively impact their quality of life. We believe the ENVISION results demonstrate a robust therapeutic benefit of givosiran treatment on the debilitating aspects of this disease. Based on these results, we believe givosiran has the potential, if approved, to be a transformative medicine for AHP patients and their families,? said Akshay Vaishnaw, M.D., Ph.D., President, R&D at Alnylam. ?We extend our profound thanks to all the patients, investigators, and study staff who participated in the ENVISION study.? ?These positive ENVISION results represent another landmark event in Alnylam?s pioneering efforts to advance RNAi therapeutics as a whole new class of medicines. Notably, givosiran is the first GalNAc-conjugate siRNA to achieve positive Phase 3 results, and the second example of Alnylam?s R&D strategy bearing fruit due to our focus on genetically validated targets for the advancement of potential high impact medicines,? said?John Maraganore, Ph.D., CEO of Alnylam. ?Assuming favorable regulatory review, we very much look forward to adding givosiran as the second product in our global commercialization efforts. Indeed, we believe today?s news brings us one important step closer to meeting our?Alnylam 2020?goals of building a multi-product, global commercial company with a deep clinical pipeline for continued growth and a robust product engine for sustainable innovation.? Givosiran has received Breakthrough Therapy and Prime designation by the?FDA?and EMA, respectively, and has Orphan Drug status in the U.S. and EU for the treatment of AHP. The Phase 1 results of givosiran were recently published in?TheNew England Journal of Medicine1.FullENVISION study results will be presented in an oral plenary session on?Saturday, April 13?at EASL in?Vienna, Austria. The ENVISION results have not yet been reviewed by regulatory authorities. ENVISION Study Results ENVISION, a randomized, double-blind, placebo-controlled trial, enrolled 94 patients with AHP (including 89 with genetically-confirmed acute intermittent porphyria [AIP], the most common subtype of AHP), at 36 study sites in 18 countries around the world, and is the largest ever interventional study conducted in AHP. Patients were randomized 1:1 to givosiran or placebo, with givosiran administered subcutaneously at 2.5 mg/kg monthly. The primary endpoint for the study was reduction relative to placebo in the annualized rate of composite porphyria attacks, defined as those requiring hospitalization, urgent healthcare visit, or hemin administration, in patients with AIP over six months. At six months, givosiran met the primary endpoint in patients with AIP (p less than 0.00000001). All the components of the composite primary endpoint and all subgroup analyses for the primary endpoint favored givosiran. Secondary endpoints listed below also demonstrated statistically significant favorable differences in the givosiran arm compared to placebo (p less than 0.0001):- Urinary ALA levels at three months in AIP patients;
- Urinary ALA levels at six months in AIP patients;
- Urinary PBG levels at six months in AIP patients;
- Annualized days of administered hemin doses in AIP patients; and
- Annualized attack rate in patients with AHP (including AIP).
View source version on businesswire.com:?https://www.businesswire.com/news/home/20190306005240/en/
Source:?Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276